Tariffs push pharma to choose: onshore or pay up
The gist
Pharma giants are being forced to pick sides: bring drug production back to the U.S. or face tariffs up to 100%—and the clock is ticking.
What to know
- U.S. domestic drug production plummeted to 37% of consumption by 2024, sparking a policy blitz for supply-chain resilience.
- By summer 2026, 17 drugmakers had publicly agreed to both cut prices and reshore manufacturing, as the government formally targeted 86 critical drugs for domestic production.
- Proposed tariffs on branded drug imports could drop from 100% to 20% for companies with onshoring deals by July 31, 2026—but critics warn this could backfire with higher costs and stifled innovation.
Resilience Over Tariffs
Policymakers in 2024 prioritized rebuilding U.S. drug manufacturing through transparency and supply-chain incentives before resorting to tariffs.
In 2024, U.S. policymakers were already framing pharmaceuticals as a resilience problem rooted in long-term erosion of domestic capacity, not simply a trade imbalance. The Senate Special Committee on Aging reported in 2024 that the United States produced 37% of the pharmaceuticals it consumed, down from 83% in 2002, and used that decline to justify a resiliency agenda centered on rebuilding upstream capability, with the 2024 recommendation emphasizing prioritizing U.S.-made APIs and key starting materials rather than relying on new tariff measures.
That same baseline shaped the executive branch response. In early April 2024, HHS proposed supply-chain resiliency programs aimed at improving transparency and resilience without using tariffs or mandates; on April 2, 2024, the Department of Health and Human Services issued a policy paper proposing the “Manufacturer Resiliency Assessment Program” and the “Hospital Resilient Supply Program” to improve supply-chain visibility through incentives and information sharing, while also favoring trade-compliant nearshore sources where domestic supply was unavailable through procurement preferences rather than tariffs.
Tariffs and Price Demands Collide
Drugmakers face unprecedented pressure as U.S. officials link lower prices and domestic manufacturing in a coordinated policy drive.
The why-now trigger is that tariff pressure is no longer operating in isolation: it is being paired with explicit government demands for cheaper medicines and domestic production, creating a combined incentive structure that companies are responding to in public. In a July interview, the U.S. Trade Representative said officials are “encourage[d]… to reshore” and cited “commitments from 17 pharmaceutical companies” that “not only… lower prices of medication here in the US” but “also agreed to… reshore here and to manufacture here,” directly linking pricing concessions and U.S. manufacturing commitments in the same policy push.
That pressure has sharpened as the administration frames foreign dependence as a supply risk and then backs that framing with a formal reshoring agenda, making import-heavy strategies harder to defend. The Trade Representative warned that “if somehow you lose access to uh Chinese inputs uh it can be a huge challenge for our own manufacturing base… one great thing that we're seeing as we try to encourage companies to reshore is we actually have” those company commitments, and by late September Becker’s Hospital Review could summarize the next escalation in a headline: “Trump administration seeks to reshore 86 critical drugs.”
Onshoring or Paying the Price
Pharma companies must choose between steep import tariffs and costly domestic investments, with new laws and capacity bottlenecks raising the stakes.
The tariff regime works by forcing drugmakers to choose between punitive import duties and a package of onshoring investments, pricing concessions, or other government-approved exemptions. Proposed 100% tariffs target branded pharma imports, with a July 31, 2026 window to negotiate onshoring agreements that could reduce the rate to 20%. Companies that negotiated deals under the President’s MFN initiative would be exempt, and regions with previously negotiated tariff deals would also be exempt. The GLP-1 fill-finish bottleneck shows the same pressure: fill-finish capacity is the sterile final step, and for more than two years GLP-1 supply was capped by a few dozen sterile filling lines.
BIOSECURE, buried as Section 851 in the FY 2026 National Defense Authorization Act signed December 18, 2025, prohibits any company that receives US federal funding from using equipment or services from designated biotech firms, so listed suppliers force contracts to wind down and new ones to stop. Western contract manufacturers — Lonza, Samsung Biologics, FUJIFILM Diosynth, and Thermo Fisher’s pharma services arm — have been quietly absorbing displaced capacity at premium pricing, while Total disclosed CDMO capacity investment in 2025 hit $24.86 billion, with $18.48 billion of that flowing into the United States. That same choose-or-pay structure appears in 1 example of GLP-1 supply, where bottlenecks pushed firms toward major capacity expansion rather than simply paying the penalty.
Tariff Risks Spark Innovation Fears
Critics warn that aggressive tariffs could disrupt drug development funding and raise healthcare costs across the entire U.S. medical supply chain.
Critics say the tariff strategy confuses resilience with coercive price suppression and could instead hollow out the economics that fund drug development. In the August 4 analysis, one speaker warned that if a U.S. price were lowered to match a price-controlled country, “you would most likely face a shareholder lawsuit… because that's basically suicidal,” noting “About 75% of global earnings in biioarma occur in the US… [and] So…” in the “extreme case,” the U.S. would end up “paying for 100% of the return to innovation” if foreign governments refused to buy or simply overrode patents.
The same backfire critique extends beyond drugs to the wider healthcare manufacturing base targeted by Section 232. Washington Examiner argued that broad tariff/trade restrictions under Section 232 could raise the cost of essential healthcare products and disrupt access for patients, physicians, and hospitals, while the Bureau of Industry and Security is “continuing its Section 232 investigation into imports of personal protective equipment (PPE), medical consumables, and medical devices.” Critics warn “premature trade” curbs could hit supply before domestic capacity scales, even as PwC estimated tariff-related costs could range from $500 million to $56 billion annually and the existing U.S. medtech base already spans “approximately 16,000 manufacturing facilities” and “nearly two million direct” and indirect jobs.
